Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face (ImiReduc)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by Nantes University Hospital
MEDA Pharma GmbH & Co. KG
Information provided by (Responsible Party):
Nantes University Hospital Identifier:
First received: October 23, 2012
Last updated: June 6, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2021
  Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)